Market News

CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023

by Ron Finklestien

Published On: March 21, 2024 11:10 pm

CMPX Stock Analysis: Compass Therapeutics Falls Short on EPS in Q4 2023

Unfolding Disappointment

CMPX stock - CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023

Source: iQoncept / Shutterstock

Challenges Unfolding

It’s a somber scene as Compass Therapeutics (NASDAQ:CMPX) discloses its fourth-quarter 2023 outcomes.

The declared earnings per share stand at -11 cents, a shy step away from the anticipated -9 cents by analysts.
Regrettably, revenue figures for the quarter remain undisclosed by the company.

InvestorPlace Earnings unravels the developments of Compass Therapeutics using insights from TradeSmith, offering an automated peek into the quarterly earnings. Data encompassing key metrics like earnings per share and revenue comparison against analyst forecasts is disbursed without manual intervention. This system enables InvestorPlace to promptly reveal the latest financial statistics to its audience. For concerns or corrections, contact us at [email protected].